Home › Markets › Industrials › OLN

Olin Corporation (OLN)

OLN trades on NYSE in Industrials, Major Chemicals. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · October 14, 2026
$14.87
+1.09% on the day
Market cap
$1.7B
Small cap
Revenue · 2025
$6.8B
+3.7% on 2024
Net income · 2025
-$101.1M
-1.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.

Profile

FieldValue
TickerOLN on NYSE
SectorIndustrials
IndustryMajor Chemicals
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000074303
SEC industry codeChemicals & Allied Products
Incorporated inVA

Financials · 2025

LineValue
Revenue$6.8B
Net income-$101.1M
Operating income$5.3M
Net margin-1.5%
Operating margin0.1%
Revenue growth+3.7%
Cash$167.6M
Total assets$7.3B
P/E (computed)Net income was not positive
P/S (computed)0.2×

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-07-13
Latest annual report
FORM 10-K
10-K2026-02-20
Latest quarterly / interim10-Q2026-07-31
Latest current report8-K2026-08-25
Latest proxy
ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS
DEFA14A2026-03-20

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-5.3%
1 month-12.0%
3 months-31.4%
Year to date-27.6%
1 year-36.9%
From 52-week high-50.0%

Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Major Chemicals

TickerCompanyPriceDayMarket cap
STDNStandard Nuclear Inc.$12.48-6.73%$2.0B
CCChemours Company (The)$13.20-1.42%$2.0B
MTXMinerals Technologies Inc.$63.83+1.40%$2.0B
HUNHuntsman Corporation$8.16+1.11%$1.4B
REXREX American Resources Corporation$42.74+3.66%$1.4B
FMCFMC Corporation$8.31-0.12%$1.3B
IOSPInnospec Inc.$97.43+1.85%$2.4B
NGVTIngevity Corporation Common Stock$70.08+1.46%$2.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier